The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA (ctDNA) assessment taken approximately 7 days after the reinjection of the CAR-T cells, in order to be able to anticipate a possible progression of the disease and to be able to propose salvage or earlier adjuvant therapy to improve patient prognosis.
No linked publications found in PubMed
Inclusion Criteria: * Patients aged 18 or over * Carriers of relapsed or refractory diffuse large cell B-cell lymphoma (LBDGC R/R), relapsed or refractory primary mediastinum B-cell lymphoma or follicular lymphoma transformed into LBDGC R/R * Patients with an indication for treatment with CAR-T anti CD19 * PET-CT pre-injection of CAR-T performed * Signed informed consent * Patients affiliated or beneficiaries of a health insurance scheme Exclusion Criteria: * Pregnant or breastfeeding women * Absence or insufficiency of tumor material (patient's most recent diagnostic biopsy) fixed in FFPE paraffin of insufficient quality/quantity for next-generation sequencing (NGS) analysis * Lack of patient consent * Patient treated with CAR-T as part of a therapeutic clinical trial * Patient whose weight is less than 30 kg * Protected adult or deprived of liberty (under guardianship or curatorship) * Patient unable to understand the study for any reason whatsoever or to comply with the constraints of the trial (language, psychological, geographic problem, etc.).